Literature DB >> 2503384

Effect of artificial electron acceptors on the cytotoxicity of mitomycin C and doxorubicin in human lung tumor cells.

H G Keizer1, S J De Leeuw, J Van Rijn, H M Pinedo, H Joenje.   

Abstract

The cytotoxicities of mitomycin C (MMC) and doxorubicin (DOX) have been proposed to depend on intracellular reduction by reduced flavoproteins. We investigated whether MMC- and DOX-induced cytotoxicity could be inhibited by competing for electrons from reduced flavoproteins by the artificial electron acceptors phenazine methosulfate (PMS), menadione (MEN) and methylene blue (MB). In intact SW-1573 human lung tumor cells these compounds proved to be excellent electron acceptors, as judged from their capacity to induce high levels of cyanide-resistant respiration. In addition, PMS, MEN and MB were found to decrease the cytotoxicity of MMC, by 90, 63 and 29%, respectively, at concentrations that were themselves completely nontoxic. In contrast, DOX cytotoxicity was not detectably affected. These results suggest that in SW-1573 cells flavoprotein-mediated bioreduction is required for the cytotoxic effect of MMC, but not for that of DOX.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2503384     DOI: 10.1016/0277-5379(89)90397-0

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN: 0277-5379


  4 in total

1.  Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy.

Authors:  Dean Lim; Robert J Morgan; Steven Akman; Kim Margolin; Brian I Carr; Lucille Leong; Oluwole Odujinrin; James H Doroshow
Journal:  Invest New Drugs       Date:  2005-06       Impact factor: 3.850

2.  Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.

Authors:  M Tetef; K Margolin; C Ahn; S Akman; W Chow; P Coluzzi; L Leong; R J Morgan; J Raschko; S Shibata
Journal:  J Cancer Res Clin Oncol       Date:  1995       Impact factor: 4.553

3.  Phase I study of mitomycin C and menadione in advanced solid tumors.

Authors:  K A Margolin; S A Akman; L A Leong; R J Morgan; G Somlo; J W Raschko; C Ahn; J H Doroshow
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

4.  Mitomycin C and menadione for the treatment of lung cancer: a phase II trial.

Authors:  M Tetef; K Margolin; C Ahn; S Akman; W Chow; L Leong; R J Morgan; J Raschko; G Somlo; J H Doroshow
Journal:  Invest New Drugs       Date:  1995       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.